Association of Immune-Related Adverse Events with Efficacy in Consolidation Nivolumab plus Ipilimumab or Nivolumab Alone after Chemoradiation in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: an exploratory analysis from the Big Ten Cancer Research Consortium study BTCRC LUN 16-081